Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M5542 in healthy participants
NCT06577337Phase 1Suspended
- Sponsor
- Merck KGaA
- Start
- Sep 2024
- Primary completion
- Dec 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing M5542 with Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events at Day 85 and Abnormal Laboratory Assessments, 12-Lead Electrocardiogram (ECG), and Vital Signs at Day 85. Started Sep 2024; status: suspended.
02
Drugs
M5542
Beyond the preview
Go deeper on NCT06577337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06577337.